Microport Cardioflow Medtech Corporation · HKEX:2160
Microport Cardioflow Medtech — H1 2024 Earnings Presentation
29 slides from Microport Cardioflow Medtech's earnings presentation, Sep 2, 2025
Slide 1: 2024 Interim Results Presentation
MicroPort CardioFlow Medtech Corporation 2024 Interim Results Presentation September 2024
Slide 2: Disclaimer
Disclaimer Disclaimer MicroPort CardioFlow Medtech Corporation This presentation was prepared by MicroPort CardioFlow Medtech Corporation (微创心通医疗科技有限公司) (the “ Company”) solely for use at the presentation for 2024 interim results. The information contained in this presentation has not been reviewed
Slide 3: Agenda
Agenda MicroPort CardioFlow Medtech Corporation Business Product Pipeline Appendix Highlights Update 04-05 10-17 22-29 Sales & Marketing Financial Review Review 06-09 18-21
Slide 4: Business Highlights
Business Highlights
Slide 5: 1H24 Highlights: Exceptional Commercialization and Fruitful Pipeline Progress
1H24 Highlights: Exceptional Commercialization and Fruitful Pipeline Progress Key Indicators Operational Highlights TAVI hospital coverage: domestic: +50 to over 600, overseas: +27 to ~100, Revenue RMB 223.1mn + 26.5%YOY continue to gain shares in top hospitals while cultivating new hospitals VitaFl
Slide 6: Sales & Marketing Review
Sales & Marketing Review
Slide 7: Healthier Growth Driven by Higher Sales Manpower Efficiency
Healthier Growth Driven by Higher Sales Manpower Efficiency China: Healthier Growth Sales Manpower Efficiency [1] 26.4% +50 3.91 2.55 Revenue Hospital coverage 1.74 RMB 215mn 603 144 132 114 +53 10.1 ppts 2022 2023 1H 2024[2] Average number of sales personnel Independent physicians Distribution cost
Slide 8: Continuous Growth Fueled by Further Market Penetration Globally
Continuous Growth Fueled by Further Market Penetration Globally China: Continuous Efforts in Enhancing Brand Promotion Non-China: Carve Out a Unique Position within Global TAVI Market Continuous efforts for market education and intragroup synergy Overseas expansion led by TAVI: implanted in 6 countr
Slide 9: Layout International Market and Expand Global Influence
Layout International Market and Expand Global Influence Major Achievements in VitaFlow Liberty® Solid Steps Toward Globalization HKSAR, approved in Q1，to be launched in Q3 CE Mark, approved in Q2 Saudi Arabia, approved in Q2, to be launched in Q3 Chile, launched in Q1 Switzerland, launched in Q3 Bel
Slide 10: Product Pipeline Update
Product Pipeline Update
Slide 11: Innovative and High-quality Total Solutions for Structural Heart Diseases
Innovative and High-quality Total Solutions for Structural Heart Diseases All-round Structural Heart Portfolio via In-House R&D and Collaboration with Global Partners 2 launched 2 under R&D 2 under R&D 4 launched 2 launched 1 Pending approval 2 launched 3 under R&D 1 under R&D 1 under R&D TAVI TMV T
Slide 12: VitaFlow Series: Positive Clinical Trial Results and KOL Endorsements
VitaFlow® Series: Positive Clinical Trial Results and KOL Endorsements VitaFlow® VitaFlow Liberty® Transcatheter Aortic Valve Implantation System Transcatheter Aortic Valve Implantation System Relatively lower all-cause mortality rate Significantly reduced intraoperative valve-in-valve incidence 1-y
Slide 13: VitaFlow Series: Positive Clinical Trial Results and KOL Endorsements
VitaFlow® Series: Positive Clinical Trial Results and KOL Endorsements VitaFlow Liberty ® Flex VitaFlow ® BE Transcatheter Aortic Valve Implantation System Transcatheter Aortic Valve Implantation System Steerable catheter expected to significantly improve patient Adopts a short stent design and dry
Slide 14: Self-developed TMVR Product: FIM Study Confirming Safety and Efficacy
Self-developed TMVR Product: FIM Study Confirming Safety and Efficacy TMVR pain points: anchoring difficulty, LVOTO risk, LV function impairment, long learning curve… World’s first dry-tissue TMVR system Low profile of stent design reducing with clinical application LVOTO (Left Ventricular Outflow T
Slide 15: AltaValve: Received Breakthrough and IDE Approval of FDA
AltaValveTM: Received Breakthrough and IDE Approval of FDA TMVR pain points: anchoring difficulty, LVOTO risk, LV function impairment, long learning curve… Product Features Supra-annular fit and atrial-only fixation design overcoming anchoring and fixation difficulties The sole known TMVR device wit
Slide 16: AnchorMan LAAC and LAAA: Enrichment of Structural Heart Portfolio
AnchorMan® LAAC and LAAA: Enrichment of Structural Heart Portfolio AnchorMan® Left Atrial Appendage Access System AnchorMan® Left Atrial Appendage Closure System Compatible with AnchorMan® Left Atrial Appendage Semi-closed structure formed by the “3D folding” Closure System, providing the femoral ve
Slide 17: Kewei's CHD Occluder: Affordable and Profitable
Kewei’s CHD Occluder: Affordable and Profitable Product Features Delivery System - Flexibility and resistance: provide good cross-ability and pushability, ASD Occluder VSD Occluder PDA Occluder easy to reach the defect site - Position accuracy: radiopaque at the tip help for real-time imaging - Ma
Slide 18: Financial Review
Financial Review
Slide 19: Rapid Revenue Growth Coupled by Increase in Gross Profit
Rapid Revenue Growth Coupled by Increase in Gross Profit Revenue (RMB’000) Gross Profit (RMB'000) Gross Profit Margin (%) 223,138 70.9% 158,224 176,442 116,623 66.1% 23 1H 24 1H 23 1H 24 1H 23 1H 24 1H Overall revenue increased by 26.5% in 1H24, driven by continued hospital penetration of our TAVI p
Slide 20: Effective Cost Control to achieve healthy and sustainable growth
Effective Cost Control to achieve healthy and sustainable growth Co-ordinate internal and external resources, enhancing operational efficiency, and driving the business to achieve healthy and sustainable growth. Our operational expenses1 vs revenue ratio decreased by 36.9 percent points from 127.4%
Slide 21: Sufficient Cash Reserve for Future Development
Sufficient Cash Reserve for Future Development Cash Outflow from Operating Activities Cash and Cash Equivalents* (RMB'000) (RMB'000) 1,773,680 1,560,426 125,212 84,854 1H 23 1H 24 End of FY23 End of 1H24 We maintained sufficient cash balance as of 30, Jun 2024 of RMB1.56 billion*, which can support
Slide 22: Appendix
Appendix
Slide 23: Appendix 1: Overview of Product Pipeline
Appendix 1: Overview of Product Pipeline Product Pre-clinical Clinical trial Registration Launched VitaFlow® Successfully registered in Argentina and Thailand VitaFlow® System Launched Alwide® balloon catheter* Successfully registered in Argentina and Thailand Launched VitaFlow Liberty® (Retrievable
Slide 24: Appendix 2: TAVI Products - Clinical Data Comparison
Appendix 2: TAVI Products - Clinical Data Comparison MicroPort CardioFlow Medtech Corporation 30-day 1-year 1-year 2-year 3-year 4-year 5-year 6-year 7-year 30-day major 1-year major moderate 1-year major 2-year major 3-year major 4-year major 5-year major 6-year major 7-year major 8-year mortality
Slide 25: Appendix 3: Product Features - TAVI
Appendix 3: Product Features - TAVI Category Product Features Progress Improved coaxial release to reduce PVL (Perivalvular leakage) and valve VitaFlow®III migration risks Self-Expanding Decreased vascular complications NMPA Registration in progress The world’s only retrievable steering motorized de
Slide 26: Appendix 3: Product Features - TMVR
Appendix 3: Product Features - TMVR Category Product Features Progress Low profile of stent design reducing LVOTO (Left Ventricular Outflow Tract obstruction) risks Completed 8 CU cases by the end of June, TMVR product Dry tissue for better biocompatibility and anti-calcification with a total of ~20
Slide 27: Appendix 3: Product Features - TTV
Appendix 3: Product Features - TTV Category Product Features Progress Minimized postoperative complications due to oversizing by reducing radial support. TTVR product Effective control of postoperative tricuspid regurgitation In R&D and design stage (In-house development) Simplified operation of the
Slide 28: Appendix 3: Product Features - Left Atrial Appendage Products
Appendix 3: Product Features - Left Atrial Appendage Products Category Product Features Progress Semi-closed structure formed by the 12 “3D folding” units and the frame: • combines the merits of an open and closed closure device AnchorMan® • solves the clinical pain point that the access sheath of t
Slide 29: Our Mission
Our Mission To provide trustworthy and universal access to state-of- the-art total solutions to treat structural heart diseases
MicroPort CardioFlow Medtech — H1 2024 Earnings Presentation on 6ix